Members of OpenBiome's leadership authored a Letter to the Editor of Nature Biotechnology in the September 2014 edition, correcting an article that gave the impression that FDA regulations had changed and OpenBiome was no longer in operation. Here is an excerpt:
"The article contained a box titled “Stool bank shut down,” indicating that OpenBiome would no longer be able to supply processed stool from rigorously screened anonymous donors for FMT. We would like to clarify that this is not the case. Current FDA guidance allows clinicians to provide FMT for patients with recurrent Clostridium difficile infection (CDI) using material either from patient-identified donors or from stool banks, such as OpenBiome. Indeed, as of July 10, OpenBiome has provided material for >600 treatments to 65 hospitals and clinics in 27 states."
Since publication, the number of treated patients has risen to more than 1000, across more than 100 partners in OpenBiome's clinical network.
The full letter, which is behind a paywall, may be available to some readers here.